Northwell Health partners with TeleTracking to bring real-time bed visibility to New York health system

Pittsburgh, PA, Nov. 12, 2020 (GLOBE NEWSWIRE) — Northwell Health, the largest healthcare provider in New York state, signed an extended agreement with TeleTracking Technologies, Inc., the capacity management and health system command center technology pioneer, to centralize operations and bring real-time bed visibility to the system’s 19 facilities.

For nearly three decades, TeleTracking has delivered enterprise technology to hundreds of health systems across the U.S., Canada and UK, providing real-time, actionable and meaningful data to make better, faster and safer decisions about patient care.

Northwell Health was squarely in the epicenter of the COVID-19 crisis that unfolded across greater New York City this past spring. The ability to effectively coordinate day-to-day activities and respond to the dynamic needs of patients, staff and the community quickly emerged as a critical need. Northwell Health’s success in mobilizing resources for the first wave of COVID-19 resulted in the creation of strong resurgence plans if a second wave emerges. In addition, as part of Governor Cuomo’s “build back better” plan, Michael Dowling, President and CEO of Northwell Health, has been tasked to lead the effort to institutionalize hospitals to operate as one system in a public health emergency.

“We have been honored to work closely with Northwell Health for a number of years and serve as a trusted partner as their enterprise vision has evolved,” says Chris Johnson, President, TeleTracking. “We worked tirelessly prior to the pandemic to help the system map long-term patient flow objectives, including aligning clinical and executive stakeholders. When COVID-19 struck, TeleTracking quickly mobilized to help manage patient logistics across the system by adding and tracking surge beds in areas like PACUs, catheterization labs, cafeterias, and other spaces across acute care locations.”

The extension of this agreement will allow Northwell Health to now see all available beds across the system. The data generated by TeleTracking will ensure more timely bed turnover processes to reduce patient delays, holds and length of stay associated with the discharge process; automate workflows and improve communications; expedite access to the right level of care; and identify and eliminate patient flow bottlenecks.

“TeleTracking’s contributions go well beyond technology. Our advisory services and client transformation teams have worked diligently to establish strong clinical workflows and continuity without disrupting operations,” adds Maria Romano, Clinical Advisor, TeleTracking.

The comprehensive, enterprise view of bed capacity across all 19 Northwell Health sites will allow the system to meet their community responsibilities and fulfill their mission.

“We consider TeleTracking more than a vendor. Every member of their team is a partner who shares our values and strategic vision to serve the people of New York and provide access to exceptional care,” concludes John D’Angelo, MD, Senior Vice President and Executive Director, Emergency Medicine Services, Northwell Health.

About TeleTracking Technologies, Inc.

For every hour patients wait for care, they face objectively worse outcomes. TeleTracking believes it is unacceptable that patients are not able to access the care they need, when they need it, due to operating inefficiencies and unnecessary cost barriers. Our mission is simple, to ensure no one waits for the care they need. And that’s why more than a decade ago, TeleTracking recognized the significant benefits of a centralized approach to managing patient flow and has implemented more than one hundred health system command centers across the United States and United Kingdom. TeleTracking has delivered extraordinary outcomes for nearly three decades that have been the subject of study by KLAS, Gartner and the RAND Corporation.

About Northwell Health

Northwell Health is New York State’s largest health care provider and private employer, with 23 hospitals and nearly 800 outpatient facilities. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 74,000 employees—17,000-plus nurses and about 4,500 physicians, including more than 3,300 members of Northwell Health Physician Partners—are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institutes. We’re training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the School of Nursing and Physician Assistant Studies.

Amie Podolak
TeleTracking Technologies, Inc.
412-736-9399
[email protected]

Arcadia Biosciences (RKDA) Announces a Series of Strategic Transactions with Bioceres Crop Solutions (BIOX)

— Arcadia receives a total of $8 million in up-front and contingent cash and 1.875 million BIOX shares —

— Arcadia sells its interest in Verdeca to Bioceres and will receive future trait royalties up to $10 million on HB4® soybean sales —

— Arcadia licenses GoodWheat™ to Bioceres in South and Central America and will receive future royalties on all GoodWheat sales —

PR Newswire

DAVIS, Calif., Nov. 12, 2020 /PRNewswire/ — Arcadia Biosciences, Inc. (Nasdaq: RKDA) today announced a series of strategic transactions with Bioceres Crop Solutions Corp (NYSE: BIOX), including the sale of its membership interest in Verdeca, a soybean joint venture the two companies formed in 2012. In another transaction, Bioceres acquired license rights to Arcadia’s GoodWheat™ technologies in South and Central America.

Under the terms of the agreement, Arcadia will receive $6 million in cash, including reimbursement of transaction related expenses and fees, with an additional $2 million in cash to be paid upon achievement by Verdeca of specific regulatory and commercial milestones. Arcadia also receives 1.875 million unregistered shares of BIOX common stock and a royalty stream up to $10 million on HB4® soybean sales.

“For more than a half-dozen years, we’ve successfully collaborated with Bioceres through our Verdeca joint venture to combine our capabilities in plant genomics, product development and global crop deregulation to bring the first drought tolerant, herbicide resistant product HB4 soybeans – to market,” said Matthew Plavan, president and CEO of Arcadia Biosciences. “We believe it’s time now to consolidate the commercial leadership of the HB4 program under Bioceres, with its strong reputation and footprint in South American agriculture, the primary target market for HB4 soybeans.”

“Receiving a sizable stake in Bioceres and ongoing HB4 royalty revenue allows Arcadia to continue sharing in the HB4 opportunity, while the cash component of the transaction further strengthens our balance sheet,” Plavan continued. “At the same time, turning over the reins to our trusted partner to consolidate critical decision making and execution enables greater agility for forward commercialization of Verdeca’s pipeline.” 

“Verdeca has been a truly successful venture between our two companies,” said Federico Trucco, chief executive officer of Bioceres Crop Solutions. “However, as we enter the HB4 commercial phase, we and our Arcadia partners agree that the joint venture is no longer an optimal structure. Therefore, we opted to acquire 100 percent ownership of Verdeca, while at the same time welcoming Arcadia as a BIOX shareholder.”

As part of the strategic transaction, Bioceres also acquired license rights to Arcadia’s GoodWheat portfolio of branded non-GMO specialty wheat products in South and Central America, along with Arcadia’s specialty safflower oil assets.

“South and Central America are important wheat markets for our GoodWheat products,” continued Plavan. “Bioceres is the ideal partner to represent our brand, as we seek to leverage their deep network of production and commercial partners together with their integrated product offerings in crop nutrition and crop protection.”

“We are very pleased to collaborate with Arcadia on its GoodWheat platform,” added Trucco. “We have followed the development and initial market reception of the GoodWheat portfolio of products in the United States and are eager to be the first to bring these high-value products to South and Central America, where we expect the grower demand to be strong and the food ingredient applications to be broad.” 

Rabobank acted as financial advisor to Arcadia Biosciences for the transactions.

About Arcadia Biosciences, Inc.
Arcadia Biosciences (Nasdaq: RKDA) is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company’s GoodHemp™ seed catalog delivers genetically superior hemp seeds and clones, applying the company’s proprietary crop innovation technology, ArcaTech™, to an emerging crop. Arcadia’s agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. For more information, visit www.arcadiabio.com

About Bioceres Crop Solutions

Bioceres Crop Solutions Corp. (NYSE American: BIOX) is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4® program, the company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit https://investors.biocerescrops.com.

About Verdeca
Verdeca, a U.S.-based joint venture between Bioceres Crop Solutions and Arcadia Biosciences, develops and deregulates soybean varieties with next-generation agricultural technologies. Working in partnership with South American growers, Verdeca aims to provide technologies that help increase crop productivity, making more efficient and sustainable use of land and water resources. For more information visit www.verdeca.com.

Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia’s, Bioceres’, Verdeca’s and their partners’ and affiliates’ ability to develop and commercialize products incorporating their traits, and complete the regulatory review process for such products, including obtaining approval from China; Bioceres’ compliance with laws and regulations that impact Verdeca’s business, and changes to such laws and regulations; Verdeca’s future capital requirements and ability to satisfy its capital needs; fluctuations in BIOX’s stock price; and the other risks set forth in Arcadia’s and Bioceres’ filings with the Securities and Exchange Commission from time to time, including the risks set forth in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2019, Bioceres’ Annual Report on Form 20-F for the year ended June 30, 2020, and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. and Bioceres Crop Solutions Corp. disclaim any obligation to update these forward-looking statements.

LinkedIn: Arcadia Biosciences

Twitter: @ArcadiaAg

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/arcadia-biosciences-rkda-announces-a-series-of-strategic-transactions-with-bioceres-crop-solutions-biox-301171794.html

SOURCE Arcadia Biosciences, Inc.

RigNet to Present Virtually and Host 1×1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18th and 19th

PR Newswire

HOUSTON, Nov. 12, 2020 /PRNewswire/ — RigNet, Inc. (NASDAQ: RNET) (the “Company”), a leading provider of ultra-secure, intelligent networking solutions and specialized applications, announced that Steven Pickett, President and Chief Executive Officer, and Lee M. Ahlstrom, Senior Vice President and Chief Financial Officer, will participate in the virtual Southwest IDEAS Investor Conference on November 18th and 19th, 2020. RigNet’s company presentation will be webcasted and is scheduled to be available at 7:00 am CST on November 18th. The presentation can be accessed through the Southwest IDEAS conference portal for registered participants on the IDEAS conference website: www.IDEASconferences.com and in the investor relations/presentations section of the Company’s website: http://www.rig.net.

About IDEAS Investor Conferences

The mission of the IDEAS Conferences is to provide independent regional venues for quality companies to present their investment merits to an influential audience of investment professionals.  Unlike traditional bank-sponsored events, IDEAS Investor Conferences are “Sponsored BY the Buyside FOR the Buyside” and for the benefit of regional investment communities.  Conference sponsors collectively have more than $200 billion in assets under management and include: Adirondack Research and Management, Allianz Global Investors: NFJ Investment Group, Ariel Investments, Aristotle Capital Boston, Barrow Hanley Mewhinney & Strauss, BMO Global Asset Management, Constitution Research & Management, Inc., Fidelity Investments, First Wilshire Securities Management, Inc., Gamco Investors, Granahan Investment Management, Great Lakes Advisors, Greenbrier Partners Capital Management, LLC, GRT Capital Partners, LLC, Hodges Capital Management, Ironwood Investment Management, Keeley Teton Advisors, Luther King Capital Management, Marble Harbor Investment Counsel, Perritt Capital Management, Punch & Associates, Westwood Holdings Group, Inc., and William Harris Investors.

The IDEAS Investor Conferences are held annually in Boston, Chicago and Dallas and are produced by Three Part Advisors, LLC.  Additional information about the events can be located at www.IDEASconferences.com.

If interested in participating or learning more about the IDEAS conferences, please contact Lacey Wesley at  (817) 769 -2373 or [email protected].

About RigNet

RigNet (NASDAQ: RNET) delivers advanced software and communications infrastructure that allow our customers to realize the business benefits of digital transformation. With world-class, ultra-secure solutions spanning global IP connectivity, bandwidth-optimized OTT applications, IIoT big data enablement, and industry-leading machine learning analytics, RigNet supports the full evolution of digital enablement, empowering businesses to respond faster to high priority issues, mitigate the risk of operational disruption, and maximize their overall financial performance. RigNet is headquartered in Houston, Texas with operations around the world. 

For more information on RigNet, please visit www.rig.net. RigNet is a registered trademark of RigNet, Inc.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rignet-to-present-virtually-and-host-1×1-investor-meetings-at-the-annual-southwest-ideas-investor-conference-on-november-18th-and-19th-301171638.html

SOURCE RigNet, Inc.

Biocept Provides Update on COVID-19 Testing with More than 100,000 Samples Received

PR Newswire

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ — Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 100,000 samples received to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory. 

“We are providing COVID-19 testing to a growing list of clients including skilled nursing centers, hospitals, clinics and surgery centers.  The majority of our customers are located in California, but we are receiving samples from across the country,” said Michael Nall, President and CEO of Biocept.  “We are committed to providing this important service during the pandemic and we continue to return the vast majority of COVID-19 test results to our customers within 48 hours of receiving a sample.  

“We expect COVID-19 RT-PCR testing will have a significant positive impact on our revenues through the remainder of the year and continuing into 2021,” he added.

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options. Additionally, Biocept is offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic. For more information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding our expectation that COVID-19 RT-PCR testing will have a significant positive impact on our revenues through the remainder of the year and continuing into 2021, and the ability of Biocept’s platform to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.


Investor Contact

:
 

LHA Investor Relations

Jody Cain

[email protected] 
310-691-7100

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-provides-update-on-covid-19-testing-with-more-than-100-000-samples-received-301171466.html

SOURCE Biocept, Inc.

Biannual State of the Home Survey Examines Impact of Pandemic on Financial Savings Strategies

Biannual State of the Home Survey Examines Impact of Pandemic on Financial Savings Strategies

NORWALK, Conn.–(BUSINESS WIRE)–
HomeServe USA (HomeServe), a leading provider of home repair solutions, announced the findings of the 11th edition of its Biannual State of the Home Survey. The survey reports on the financial impact of home repairs and the state of the American home. This edition, in light of COVID-19, also looked at whether Americans have changed their financial savings strategy as a result of the pandemic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201112005174/en/

Infographic on HomeServe's 11th edition of its Biannual State of the Home Survey (Photo: Business Wire)

Infographic on HomeServe’s 11th edition of its Biannual State of the Home Survey (Photo: Business Wire)

“2020 has, without a doubt, been a year of significant turmoil. So for the 11th edition of our survey, we wanted to provide some measurement of the impact uncertainty and the COVID-19 pandemic has had on our lives,” said Tom Rusin, Global CEO of HomeServe Membership. “The survey made it clear that the pandemic has impacted many Americans’ financial savings strategies, with a significant number – 43% – indicating that they are trying to save more for the future than they were prior as a result of COVID-19. This is especially significant coupled with the survey finding that over one-third of homeowners (36%) have less than $500 – or nothing at all – set aside for an emergency home repair, yet 62% of homeowners have had a home repair emergency in the past 12 months.”

This edition of the survey was conducted online by The Harris Poll on behalf of HomeServe, September 16-18, 2020, among 2,053 U.S. adults age 18+, of which 1,424 are homeowners.

Americans’ Savings Practices Now and Post COVID-19

The survey looked at how COVID-19 has impacted Americans’ strategy for saving financially for the future. Forty-three percent of Americans say they are trying to save more for the future than they were before as a result of the pandemic; with 53% of those age 18-36 saying they are trying to save more. On the other side, 13% of Americans say they will likely save less than they were before as a result of COVID-19.

Each of the 11 editions of the survey have measured homeowners’ savings practices for unexpected home emergencies. This edition of the survey found that over one-third (36%) of homeowners have less than $500 or nothing set aside for an emergency home repair. Nearly one in five homeowners (19%) with an annual household income of less than $50,000 reported having no savings set aside for such an emergency. The lack of savings is especially concerning given that more than three out of five (62%) homeowners reported having a home repair emergency in the past 12 months.

Twenty-one percent of homeowners in the Midwest reported having no funds set aside for a home emergency repair, while only 9% of homeowners in the Northeast and West have no savings for such a repair.

Homeowners Tackle Home Repairs and Decorating During COVID-19

It’s not surprising that American homeowners are taking advantage of more time at home during quarantine to make the spaces they live in more enjoyable. Spending more time at home has caused nearly one-third of homeowners (31%) to want to renovate or redecorate their home and one-third (32%) report that it has allowed them to tackle some needed home repairs. This trend is reinforced by the 20% increase in demand for repair services that HomeServe has seen from its customers since the pandemic began.

Additionally, almost one-quarter of Americans (24%) say that more time at home has made them realize how much they love the spaces they live in. On the flip side, 15% of Americans report that spending more time at home during quarantine has made them want to move to a new home with those ages 18-36 being more likely than those ages 37+ to say this (24% vs. 11%).

For more information on available repair service plans, visit www.HomeServeUSA.com and for helpful homeowner tips, visitwww.HomeServeUSA.com/blog.

Survey Methodology

This survey was conducted online within the United States by The Harris Poll on behalf of HomeServe from September 16-18, 2020 among 2,053 U.S. adults ages 18 and older (among whom 1,424 are homeowners). This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact [email protected].

About HomeServe

HomeServe USA Corp. (HomeServe) is a leading provider of home repair solutions serving more than 4.4 million customers across the US and Canada under the HomeServe, Home Emergency Insurance Solutions, Service Line Warranties of America (SLWA), Service Line Warranties of Canada (SLWC) names, and through locally branded HVAC companies located in major metro areas. Since 2003, HomeServe has been protecting homeowners against the expense and inconvenience of water, sewer, electrical, HVAC and other home repair emergencies by providing affordable repair coverage, installations and quality local service.

As an A+ rated Better Business Bureau Accredited Business, HomeServe is dedicated to being a customer-focused company supplying best-in-class repair plans and other services to consumers directly and through over 1,000 leading municipal and utility partners.

HomeServe has teamed up with executive producer, host, and best-selling author Mike Rowe, best known as the creator and host of the hit TV series Dirty Jobs, to work together to provide homeowners expert advice on maintaining, enhancing and protecting their homes. For more information about HomeServe, a Great Place To Work certified winner and recipient of thirty 2020 Stevie Awards for Sales & Customer Service, or to learn more about HomeServe’s affordable repair plans, please go to www.homeserve.com. Connect with HomeServe on Facebook and Twitter @HomeServeUSA. For news and information follow on Twitter @HomeServeUSNews.

Myles Meehan

HomeServe USA

Phone: 203-356-4259

Email: [email protected]

Claire Deneen

Hill+Knowlton Strategies for HomeServe

Phone: 312-255-3134

Email: [email protected]

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Professional Services Utilities Residential Building & Real Estate Insurance Energy Construction & Property

MEDIA:

Logo
Logo
Photo
Photo
Infographic on HomeServe’s 11th edition of its Biannual State of the Home Survey (Photo: Business Wire)

Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

  • Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST

Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 12:35 PM EST.

A live audio webcast of the presentation will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com. The webcast replay will be available approximately two hours after the event and will be archived for 90 days.

About Corbus 

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.

Lenabasum is not approved for the treatment of any indication. For more information on Corbus’ clinical programs, please visit here.

For more information, visit http://www.corbuspharma.com/, and connect with us on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corbus Pharmaceuticals Contacts:

Ted Jenkins, Senior Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7745
Email: [email protected]

Lindsey Smith, Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7749
Email: [email protected]

Enmotus Honored with Most Innovative Flash Memory Consumer Application for Best of Show Award at Flash Memory Summit 2020

FuzeDrive SSD Key for Gaming Applications

SANTA CLARA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Enmotus was honored with a Flash Memory Summit 2020 Best of Show Award for Most Innovative Flash Memory Consumer Application at today’s Flash Memory Summit 2020 Best of Show Awards ceremony.

The Flash Memory Summit, the World’s largest and most prestigious storage industry conference and exposition, recognizes Enmotus’ FuzeDrive SSD as an exciting product for high end gaming applications.

“Gaming applications require SSDs that can adapt in real time to user and OS workloads in order to achieve high performance and endurance with big capacities for today’s games,” said Jay Kramer, Chairman of the Awards Program and President of Network Storage Advisors Inc. “We are proud to recognize Enmotus FuzeDrive SSD utilizing Artificial Intelligence (AI) to intelligently place data on appropriate media to maximize performance and endurance.”

“A new SSD architecture is needed to create an SSD that is designed for the gaming industry in a way that can achieve accelerated performance, high capacity and long endurance at a lower cost,” said Jay Kramer, Chairman of the Awards Program and President of Network Storage Advisors Inc. “We are proud to recognize Enmotus FuzeDrive SSD for applying artificial intelligence to a mix of SLC and QLC NAND and achieving better price/performance than legacy TLC solutions.”

“The application of AI to actively manage SSD flash in gaming environments provides an entirely new approach to achieving smooth, consistent and long-lasting performance without sacrificing capacity,” said Andy Mills, CEO of Enmotus. ”The Enmotus team are delighted and very much appreciate the recognition for their hard work and persistence over the past year,” he added.

According to show organizers, a record number of award submissions were received this year making the judging challenging and each of the categories extremely competitive.

Details of the award-winning companies, innovative products and solutions can be found at: https://flashmemorysummit.com/English/News_Info/Best_of_Show/BOS_Winners.html.

Supporting Resources

About Flash Memory Summit

Flash Memory Summit showcases the mainstream applications, key technologies, leading vendors, and innovative startups driving the multi-billion-dollar non-volatile memory and SSD markets. FMS is now the world’s largest event featuring the trends, innovations, and influencers leading the adoption of flash memory in demanding enterprise storage, high-performance computing, and cloud systems.

About
Enmotus

Enmotus’ Artificial Intelligent Storage Software enables fully autonomous data storage that self manages, and self optimizes based on IO activity. The Enmotus engine analyzes all IO activity, sizes the active data set, and dynamically distributes IOs across virtualized pooled resources to maximize performance according to application needs. For more information visit www.enmotus.com

Media Contacts

Semler Scientific Expands Board of Directors with Appointment of Policy Expert Cindy Moon

PR Newswire

SANTA CLARA, Calif., Nov. 12, 2020 /PRNewswire/ — Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced the appointment of Cindy Moon, a D.C.-based, healthcare payment policy expert, to its Board of Directors, effective November 10, 2020. With this addition, Semler’s Board now totals five members.

“Cindy’s expertise in shaping federal healthcare policy and promoting health system transformation will be a valuable asset to bring to the Semler Board,” stated Douglas Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. “We welcome Cindy to our Board and expect to leverage her significant policy experience as we continue to execute on our growth goals, intending to have meaningful impact on the care of patients with chronic diseases.”   

Ms. Moon is Vice President of Health Care Payment and Delivery Reform with Hart Health Strategies Inc., a bipartisan consulting and lobbying firm specializing in legislative and regulatory health care issues. Prior to joining Hart Health Strategies Inc., Ms. Moon worked at the White House Office of Management and Budget (OMB) where she advised on policy solutions affecting the Medicare program. In this role, Ms. Moon collaborated with federal stakeholders across the Executive Office of the President, the Department of Health and Human Services Office of the Secretary, and the Centers for Medicare and Medicaid Services (CMS) to oversee implementation of major payment and programmatic changes to the Medicare program.  Prior to joining OMB, Ms. Moon held successively increasing leadership positions within the Health Plan of San Mateo, a quasi-public health plan offering publicly-sponsored health coverage for qualifying residents of San Mateo County, California. Ms. Moon earned her Master of Public Policy and Master of Public Health from the University of California at Berkeley and her Bachelor of Arts from Harvard University.

About Semler Scientific, Inc.

Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers.  Semler Scientific’s mission is to develop, manufacture and market innovative proprietary products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific commercially launched its first patented and U.S. Food and Drug Administration, or FDA, cleared product in 2011, and received FDA 510(k) clearance for QuantaFlo®, the next generation version of this product, in 2015. QuantaFlo® is a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. QuantaFlo® is used by Semler Scientific’s customers to more comprehensively evaluate their patients for risk of heart attacks and strokes. Semler Scientific believes it is positioned to provide valuable information to its insurance company and physician customers, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at semlerscientific.com.

CONTACT:

Susan A. Noonan

S.A. Noonan Communications
[email protected]
212 966 3650

 

Cision View original content:http://www.prnewswire.com/news-releases/semler-scientific-expands-board-of-directors-with-appointment-of-policy-expert-cindy-moon-301171746.html

SOURCE Semler Scientific, Inc.

Nearly 4 In 10 Workers Are Suffering From Video Call Fatigue, Robert Half Research Shows

Technical Issues and Too Many Participants Are Biggest Virtual Meeting Pet Peeves

PR Newswire

MENLO PARK, Calif., Nov. 12, 2020 /PRNewswire/ — A new study by global staffing firm Robert Half shows video calls may be wearing on workers. More than three-quarters of professionals surveyed (76%) said they participate in virtual meetings. Those respondents reported spending nearly one-third of their workday (30%) on camera with business contacts or colleagues. In addition:

  • 38% said they’ve experienced video call fatigue since the start of the pandemic.
  • 26% noted that the practicality and novelty of videoconferencing has worn off over the past 8 months.
  • 24% confirmed they find virtual meetings inefficient and exhausting and prefer to communicate via other channels, like email or phone.
  • The most common video call pet peeves were dealing with technical issues (28%) and too many meeting participants and people talking over each other (19%).
  • 1 in 4 working parents (25%) reported spending more than half of their on-the-job hours in virtual meetings.
  • More women (47%) than men (32%) said they’re tired of videoconferencing.

“Video calls became the go-to way for professionals to connect, collaborate and build rapport at the start of the pandemic,” said Paul McDonald, senior executive director of Robert Half. “While effective in some instances, they can be draining in others and are best used in moderation.”

McDonald added, “Workers are busier than ever and strapped for time. Before setting up a video call, always determine the goal and if it can be accomplished via other means.”

Robert Half offers three tips for helping professionals make the most of video calls:

  1. Test your tech. Check your computer’s camera, microphone and internet connection. Close any unused programs to increase your bandwidth and reduce the temptation to multitask.
  2. Limit the guest list. Small groups tend to be more effective and engaged. Make sure everyone you invite has something valuable to offer and a stake in the outcome.
  3. Set expectations from the get-go. Send an agenda and supporting materials in advance so participants can prepare. During the discussion, capture notes and action items to share in a recap.

For more videoconference etiquette tips, visit the Robert Half blog.

About the Research
The online survey was developed by Robert Half and conducted by an independent research firm from October 27 to November 2, 2020. It includes responses from more than 1,000 workers 18 years of age or older and normally employed in office environments in the United States.

About Robert Half
Founded in 1948, Robert Half is the world’s first and largest specialized staffing firm. The company has more than 300 staffing locations worldwide and offers hiring and job search services at roberthalf.com. For additional management and career advice, visit the Robert Half blog at roberthalf.com/blog.

 

Cision View original content:http://www.prnewswire.com/news-releases/nearly-4-in-10-workers-are-suffering-from-video-call-fatigue-robert-half-research-shows-301171753.html

SOURCE Robert Half

Bishop Fox Rounds Out Advisory Board with Former Microsoft, Netscape/AOL Marketing and Product Executive

Martina Lauchengco Joins Recently Appointed Advisors Alex Stamos and Evan Wolff

PHOENIX, Nov. 12, 2020 (GLOBE NEWSWIRE) — Bishop Fox, the largest private professional services firm focused on offensive security testing, today announced that it has appointed its newest advisor Martina Lauchengco to the company’s Advisory Board. Lauchengco brings a wealth of experience in building, branding, and launching market-defining software in the technology market and helped define categories for some of the world’s most well-known companies. Lauchengco joins recently appointed Advisory Board members Alex Stamos and Evan Wolff, both leaders and icons in the security community, and will broaden the Board’s expertise as Bishop Fox elevates its portfolio of services for organizations around the globe.   

“Martina brings decades of experience in product marketing, product management, and launching category-defining new products in the technology space,” said Bishop Fox Co-founder and CEO Vinnie Liu. “We’re incredibly fortunate to have her join our Advisory Board as she’s extremely talented and well-revered in the industry and by her peers. Her in-depth marketing strategy and product marketing knowledge will help Bishop Fox foster even greater awareness for our consulting and Continuous Attack Surface Testing (CAST) services. Each member of our Board of Advisors brings a diverse skillset and experience to the table, and they share a common mission—making a positive and long-lasting impact on securing the world’s digital infrastructure.”

Lauchengco has more than 25 years of experience serving as a marketing and product executive, helping to build, brand and launch software at some of today’s most recognized organizations. She began her career at Microsoft where she was a product manager for both Microsoft Word and Microsoft Office as they became the ubiquitous productivity tools that are still widely used today. After spending several years at Microsoft, she joined Netscape in its early days where she led product management teams for the company’s original Netscape Navigator browser, the dominant web browser in market share in the 1990s. She then led marketing prior to becoming the CEO’s Chief of Staff at Loudcloud, one of the first companies to offer software as a service (SaaS).

Since then, she has gone on to help hundreds of companies navigate their go-to-market strategies as a Partner at Silicon Valley Product Group (SVPG), a consulting group, where she worked with companies including: Google, Atlassian, EMC, Symantec, and Workiva among many others. Lauchengco sits on more than a dozen B2C and B2B Boards at startups as either a director or advisor, and she’s also a lecturer on marketing and product management at the UC Berkeley graduate school of engineering. She earned a B.A. in Political Science from Stanford University and a M.A. in Organizational Behavior from Stanford University.

About Bishop Fox


Bishop Fox
is the largest private professional services firm focused on offensive security testing. Since 2005, the firm has provided security consulting services to the world’s leading organizations — working with over 25% of the Fortune 100 — to help secure their products, applications, networks, and cloud resources with penetration testing and security assessments. In February 2019, Bishop Fox closed $25 million in Series A funding from ForgePoint Capital, which will allow the company to continue to grow its research capabilities and develop next generation offensive security technologies like CAST. The company is headquartered in Phoenix, AZ and has offices in San Francisco, CA and Barcelona, Spain.

Media Contact:
Jennifer Torode
CHEN PR for Bishop Fox
[email protected]
781.672.3119

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d0a12df6-aea7-4595-9da1-6b6a3ba0612b